IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy.
Results of second-line chemotherapy regimens against lymphoma have usually been poor. In this study, we used a combination of ifosfamide, methotrexate, and VP-16 to treat 52 patients with lymphoma who had either relapsed or who had failed to attain a complete remission on front-line treatment. Thirty-two patients (62%) responded (CR 37%, PR 25%) and 10 (19%) had a minor response. The median relapse-free interval of the responding patients was 12 mo, and the median survival of the whole group was 15 mo. Of the 18 patients who achieved complete remission, 10 still remain free of any evidence of disease. The factor that best predicted for response to IMVP-16 was the quality of the remission achieved on front-line therapy. In view of the poor prognosis associated with recurrent lymphoma, the results obtained with this study are considered most encouraging. Patients with recurrent lymphoma can be successfully salvaged by the use of this combination regimen, especially if introduced early after relapse or preferably before progressive disease develops.
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols; D001424:Bacterial Infections / Q000209:etiology; D003520:Cyclophosphamide / Q000031:analogs & derivatives*; D004359:Drug Therapy, Combination; D005047:Etoposide / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage* / Q000009:adverse effects; D007249:Inflammation / Q000139:chemically induced; D008223:Lymphoma / Q000188:drug therapy* / Q000401:mortality; D008727:Methotrexate / Q000008:administration & dosage* / Q000009:adverse effects; D009092:Mucous Membrane / Q000187:drug effects; D009503:Neutropenia / Q000139:chemically induced; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D012008:Recurrence
D005047:Etoposide; D003520:Cyclophosphamide; D011034:Podophyllotoxin; D007069:Ifosfamide; D008727:Methotrexate